Evaluation of Interventions to Improve Management of Behavioural and Psychological Symptoms of Dementia (BPSD) in a Residential Care Facility

Léa Tremblay, B.Sc.(Pharm).; Jane de Lemos, B.Sc.(Pharm)., PharmD, M.Sc.; Jo Chang, B.Sc.(Pharm)., ACPR; Jarred Kelly; Michael Wilkins-Ho, MD, FRCPC; Robert Wakefield, MD, RCPSC; Jacky Siu, B.Sc.(Pharm)., ACPR, PharmD

Background

- BPSD occurs in 80% of nursing home residents with dementia
- Non-pharmacological measures are first-line treatment
- Antipsychotics increase absolute mortality rate by 1% in elderly people with dementia and are only effective for aggression, agitation, and psychosis
- Despite this, antipsychotic prescribing has increased from 37% in 2001/02 to 50.3% in 2010/11 in BC residential care facilities
- Recent interventions to improve BPSD treatment in VCH:
 - 1. Feb. 2011: VCH guideline for antipsychotic use in BPSD
 - 2. Dec. 2010: Quality Actions initiative to prompt pharmacists to make specific assessments in BPSD management
 - Number of pharmacist assessments increased from 52 in 2011 to 120 in 2012
- Aim: to assess whether these interventions have improved the management of BPSD in residential care

Methods

Design: Retrospective observational study

Population: Residents with dementia at a VCH residential care facility

Inclusion Criteria:

- Resident during 1 Jul 31 Dec of 2010, 2011, or 2012
 - Pre-intervention: 2010; Post-intervention: 2011 and 2012
- Antipsychotic initiation during above time period; defined as:
 - 1. New antipsychotic (AP) initiated in facility,
 - 2. Re-initiation of AP on admission,
 - 3. Re-initiation of previously discontinued AP therapy, or
 - 4. Regular AP ordered when previously PRN

Exclusion Criteria:

Antipsychotic ordered for less than 24 hours

Primary Outcome: To determine if the proportion of residents receiving appropriate initial antipsychotic therapy increased after implementation of above interventions

Secondary Outcome: To identify if re-assessment for efficacy and tapering of antipsychotics improved after implementation of above interventions

Statistical Analysis: Fisher's Exact Test, 1-sided

Appropriate initial antipsychotic: Consensus definition

All five criteria must be met for appropriateness

- Low dose initiated, or if re-initiated, dose maintained or decreased
- 2. Target symptom documented
- 3. Target symptom appropriate (aggression, agitation, psychosis)
- 4. Non-pharmacological measures (NPM) documented prior to antipsychotic initiation
- 5. NPM documented concurrently with antipsychotic initiation

Table 1. Baseline characteristics

| Characteristic | 2010 (n=22) | 2011 (n=14) | 2012 (n=13) | Total (n=49) |
|---------------------------------------|--------------------|--------------------|--------------------|---------------------|
| Age – average years | 84 | 81 | 83 | 83 |
| Male sex - % | 55 | 50 | 23 | 45 |
| Dosing frequency - % | | | | |
| Regular | 50 | 64 | 62 | 57 |
| PRN | 82 | 79 | 85 | 82 |
| Reason for eligibility - % | | | | |
| 1. New antipsychotic (AP) in facility | 14 | 29 | 23 | 20 |
| 2. Re-initiation of AP on admission | 73 | 57 | 62 | 65 |
| 3. Re-initiation of previously d/c AP | 5 | 7 | 15 | 8 |
| 4. Regular AP ordered, previously PRN | 9 | 7 | 0 | 6 |

Table 2. Primary outcome: Appropriateness of initial antipsychotic therapy

| Time _I | period | Appropriate | P-value* | |
|-------------------|-------------|-------------|----------|--|
| Pre-Intervention | 2010 (n=22) | 4 (18%) | | |
| Post-Intervention | 2011 (n=14) | 3 (21%) | 0.567 | |
| | 2012 (n=13) | 1 (8%) | 0.374 | |

Table 3. Secondary outcomes: Reassessments (R/A) for efficacy (within 8 weeks) and for taper (within 6 months)

| Time period | | R/A for efficacy | | | R/A for taper | | |
|-------------|------|---------------------|---|--|---|--|--|
| | | # R/A | P-value* | n** | # R/A | P-value* | |
| 2010 | 15 | 7 (47%) | | 15 | 12 (80%) | | |
| 2011 | 14 | 9 (64%) | 0.261 | 9 | 6 (67%) | 0.397 | |
| 2012 | 12 | 10 (83%) | 0.058 | 9 | 7 (78 %) | 0.640 | |
| | 2010 | n** 2010 15 2011 14 | n** # R/A 2010 15 7 (47%) 2011 14 9 (64%) | n** # R/A P-value* 2010 15 7 (47%) 2011 14 9 (64%) 0.261 | d n** # R/A P-value* n** 2010 15 7 (47%) 15 2011 14 9 (64%) 0.261 9 | d n** # R/A P-value* n** # R/A 2010 15 7 (47%) 15 12 (80%) 2011 14 9 (64%) 0.261 9 6 (67%) | |

^{*}P-value calculated between 2010 and the time period listed







Figure 1. Number of criteria met for appropriateness





Figure 2. Appropriateness of individual criteria



Results

- No statistical difference was observed in appropriateness of initial antipsychotic pre- and post-intervention implementation
- Lack of NPM was largest contributor for inappropriateness
- Trend towards increased rates of R/A for efficacy after intervention implementation

Strengths and limitations

| Strengths | • | Pilot study to define and evaluate appropriateness of antipsychotic initiation | | | |
|-------------|--|--|--|--|--|
| Limitations | Single-site study, small sample size | | | | |
| | • | Dementia incidence and antipsychotic prevalence in residents with dementia was not evaluated | | | |
| | | Limited by charting quality and continuity of care | | | |

from previous facilities in newly admitted residents

Conclusions

- Our study failed to show an increase in appropriateness of antipsychotic pre- and post-intervention implementation
- Future directions should focus on improving implementation of NPM to improve management of BPSD



^{**} n eligible for reassessment